In vitro and in vivo administration of anti-CD26 mAb inhibits tumor growth, migration and invasion via multiple mechanisms of action, leading to enhanced survival of mouse xenograft models inoculated with various cancers including renal cell carcinoma (RCC) and malignant mesothelioma (MM) [3–7]. The gene discussed is DPP4; the disease is Miyoshi myopathy.